Current hurdles in AAV-based gene therapy for hemophilia

Current hurdles in AAV-based gene therapy for hemophilia

How can we improve the efficacy and safety of gene therapy?Подробнее

How can we improve the efficacy and safety of gene therapy?

The future generations of gene therapy for hemophiliaПодробнее

The future generations of gene therapy for hemophilia

A History of Hemophilia Treatment Factor Replacement to Gene TherapyПодробнее

A History of Hemophilia Treatment Factor Replacement to Gene Therapy

AAV gene therapies for hemophilia A and BПодробнее

AAV gene therapies for hemophilia A and B

Current AAV Hemophilia B Gene Therapy TrialsПодробнее

Current AAV Hemophilia B Gene Therapy Trials

AAV-based gene therapy in hemophilia A and B: valoctocogene roxaparvovec & etranacogene dezaparvovecПодробнее

AAV-based gene therapy in hemophilia A and B: valoctocogene roxaparvovec & etranacogene dezaparvovec

Gene Therapy for Treatment of Hemophilia: AAV Vector Gene Therapy Application to HemophiliaПодробнее

Gene Therapy for Treatment of Hemophilia: AAV Vector Gene Therapy Application to Hemophilia

Gene Therapy for HemophiliaПодробнее

Gene Therapy for Hemophilia

Gene Therapy for Treatment of Hemophilia: An Introduction to AAV Vector Gene TransferПодробнее

Gene Therapy for Treatment of Hemophilia: An Introduction to AAV Vector Gene Transfer

Improved joint health following dirloctocogene samoparvovec gene therapy in patients with hemophiliaПодробнее

Improved joint health following dirloctocogene samoparvovec gene therapy in patients with hemophilia

Multiyear Factor VIII Expression after Adeno‐associated Virus Gene Transfer for Hemophilia AПодробнее

Multiyear Factor VIII Expression after Adeno‐associated Virus Gene Transfer for Hemophilia A

Gene Therapy in Hemophilia: An Introduction to AAV Vector Gene TransferПодробнее

Gene Therapy in Hemophilia: An Introduction to AAV Vector Gene Transfer

Exigency study: exploring the impact of steroids following gene therapy for hemophiliaПодробнее

Exigency study: exploring the impact of steroids following gene therapy for hemophilia

The challenges of implementing gene therapies for hemophilia in clinical practiceПодробнее

The challenges of implementing gene therapies for hemophilia in clinical practice

3. Current and Future Gene Therapy in Hemophilia, Prof. John Pasi, London, UkПодробнее

3. Current and Future Gene Therapy in Hemophilia, Prof. John Pasi, London, Uk

Recent Advances in Gene Therapy for Hemophilia Presented at NHF 2021Подробнее

Recent Advances in Gene Therapy for Hemophilia Presented at NHF 2021

David Lillicrap, MD, discusses AAV gene therapy in a canine hemophilia modelПодробнее

David Lillicrap, MD, discusses AAV gene therapy in a canine hemophilia model

Promising novel agents for hemophilia A/B: gene therapies and extended half-life productsПодробнее

Promising novel agents for hemophilia A/B: gene therapies and extended half-life products

Spark's hemophilia gene therapy reduced bleeds by 97% trialПодробнее

Spark's hemophilia gene therapy reduced bleeds by 97% trial

Synthetic AAV vectors for gene therapy of hemophilia in childrenПодробнее

Synthetic AAV vectors for gene therapy of hemophilia in children

Gene Therapy in HemophiliaПодробнее

Gene Therapy in Hemophilia

Популярное